CAR T-Cell Therapy Not Linked to Increased Risk of Second Cancers, Study Shows
核心洞察
A systematic review of over 5,500 lymphoma (搜索) and myeloma (搜索) patients found a 5.8% overall incidence of second primary malignancies (SPMs) after CAR T-cell therapy.
The risk of developing SPMs was similar between patients receiving CAR T-cell therapy and those undergoing standard of care treatments in randomized trials.
Hematologic malignancies (搜索) were the most common SPM subtype, followed by solid tumors (搜索) and nonmelanoma skin cancers, with T-cell malignancies (搜索) being rare.
A new study published in Clinical Cancer Research suggests that CAR T-cell therapy does not increase the risk of developing second primary malignancies (SPMs) compared to standard cancer treatments. The systematic review and meta-analysis, encompassing data from over 5,500 patients with lymphoma (搜索) and myeloma (搜索), offers reassurance regarding the long-term safety of this innovative immunotherapy.
The research team, led by Tobias Tix from LMU Klinikum (搜索) in Munich, analyzed data from 18 clinical trials and seven real-world studies to determine the frequency and types of SPMs occurring after CAR T-cell therapy. The overall SPM point estimate was 5.8% with a median follow-up of 21.7 months.
Similar SPM Risk Compared to Standard Care
Importantly, a subgroup meta-analysis of four trials that randomized patients to either CAR T-cell therapy or standard of care found no significant difference in SPM risk between the two groups. This suggests that the risk of secondary cancers is not elevated by CAR T-cell treatment itself.
Factors Influencing SPM Development
The study identified several factors that may influence the development of SPMs. These include the treatment setting (clinical trials versus real-world settings), the duration of follow-up, and the number of previous treatment lines a patient had received. Meta-regression analysis confirmed these as independent risk factors at the study level.
Types of Second Primary Malignancies
Among the SPMs identified, hematologic malignancies (搜索) were the most common (37%), followed by solid tumors (搜索) (27%) and nonmelanoma skin cancers (16%). T-cell malignancies (搜索) were rare, accounting for only 1.5% of cases.
Implications for Clinical Practice
"By understanding the factors contributing to SPM development and implementing effective monitoring strategies, health care providers can optimize patient outcomes and ensure the long-term safety of CAR T-cell therapies," the authors wrote. The findings underscore the importance of long-term monitoring and vigilance for SPMs in patients who have received CAR T-cell therapy, particularly those with a history of extensive prior treatments.